STATUS: Recruiting

SPONSOR: AGO Study Group
LEAD GROUP: AGO
ENGOT Model: A
TITLE: Niraparib vs Niraparib in combination with Bevacizumab in patients with carboplatinum-taxane based chemotherapy in advanced ovarian cancer (A multicentre randomised phase III trial)
ClinicalTrials.gov ID: NCT05009082

MaNGO sites (click to see the list)

STATUS: Recruiting

SPONSOR: NOGGO
LEAD GROUP: NOGGO
ENGOT Model: B
TITLE: A Phase II randomized, open label, non-inferiority study of NiraParib maintenance after 3 vs. 6 cycles of platinum-based chemotherapy in completeLy debUlked advanced HRDpositive high-grade ovarian cancer patientS in first line therapy
ClinicalTrials.gov ID: NCT05460000
MaNGO Sites (click to see the list)

STATUS: Recruiting

SPONSOR: GINECO
LEAD GROUP: GINECO
ENGOT Model: A
TITLE: A Randomized Study of Paclitaxel – Carboplatin followed by maintenance Niraparib compared to Paclitaxel – Carboplatin – Bevacizumab followed by maintenance Niraparib + Bevacizumab in Patients With Advanced Ovarian Cancer Following a Front-Line Complete Cytoreductive Surgery
ClinicalTrials.gov ID:  NCT05183984
MaNGO Sites (click to see the list)

STATUS: Recruiting

SPONSOR: Daiichi Sankyo
LEAD GROUP: GINECO
ENGOT Model: C
TITLE: A Phase 2/3, Multicenter, Randomized Study of Raludotatug Deruxtecan (R-DXd), a CDH6-directed Antibody-drug Conjugate, in Subjects with Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancers
ClinicalTrials.gov ID: NCT06161025   
MaNGO Sites (click to see the list)

STATUS: Planned
SPONSOR: European Cancer Patient Coalition

LEAD GROUP: GINECO
ENGOT Model: A
TITLE: A pragmatic randomized phase III trial to assess the utility of adjusting chemotherapy dose & dosing schedule with the SALVage weekly dose-dense regimen in patients with poor prognostic OVARian cancers based on the tumor primary chemosensitivity and incomplete debulking surgery.”
ClinicalTrials.gov ID: NCT06476184
MaNGO Sites (click to see the list)

STATUS: Recruiting

SPONSOR: Verastem, Inc.
LEAD GROUP: NCRI
ENGOT Model: C
TITLE: A Phase 3, Randomized, Open-Label Study of Combination Therapy with Avutometinib plus Defactinib Versus Investigator’s Choice of Treatment in Patients with Recurrent Low-Grade Serous Ovarian Cancer (LGSOC)
ClinicalTrials.gov ID: NCT06072781
MaNGO Sites (click to see the list)

STATUS: Recruiting

SPONSOR: Merck Sharp & Dohme LLC

LEAD GROUP: GEICO
ENGOT Model: C
TITLE: A Phase 3, Randomized, Open-label, Multicenter Study to Evaluate the Efficacy and Safety of MK-2870 Maintenance Treatment With or Without Bevacizumab Versus Standard of Care After Second-line Platinum-based Doublet Chemotherapy in Participants With Platinum-sensitive Recurrent Ovarian Cancer
ClinicalTrials.gov ID: NCT06824467
MaNGO Sites(click to see the list)

STATUS: Recruiting

SPONSOR: Merck Sharp & Dohme LLC

LEAD GROUP: GINECO
ENGOT Model: C
TITLE: Phase 3, Randomized, Open-label, Multicenter Study of MK-2870 Maintenance With or Without Bevacizumab Versus Standard of Care in Participants With Newly-Diagnosed Advanced HRD-Negative Ovarian Cancer Following First-line Platinum-based Chemotherapy
ClinicalTrials.gov ID: NCT06132958
MaNGO Sites (click to see the list)

STATUS: Recruiting

SPONSOR: Daiichi Sankyo, Inc.

LEAD GROUP: GEICO
ENGOT Model: C
TITLE: A Phase 3, Open-label, Multicenter, Randomized Trial of Trastuzumab Deruxtecan with Bevacizumab Versus Bevacizumab Monotherapy as First-line Maintenance Therapy in HER2-Expressing Ovarian Cancer
ClinicalTrials.gov ID:  NCT06819007

STATUS: Recruiting

SPONSOR: Astrazeneca

LEAD GROUP: MaNGO
ENGOT Model: C
TITLE: Phase 3 study of AZD5335 vs. Mirvetuximab Soravtansine in FRα-High and AZD5335 vs. Investigator’s Choice Chemotherapy in FRα-Low Advanced High-Grade Platinum-Resistant Epithelial Ovarian Cancer (TREVI-OC-01)
ClinicalTrials.gov ID: NCT07044336

MaNGO Sites (click to see the list)

STATUS: Planned
SPONSOR: Genmab

LEAD GROUP: BGOG
ENGOT Model: C
TITLE: A Randomized, Open-Label, Phase 3 Study of Rinatabart Sesutecan (Rina-S) Plus Standard of Care Versus Standard of Care as Maintenance Treatment After 2L Platinum-Based Doublet Chemotherapy in Participants With Recurrent Platinum- Sensitive Ovarian Cancer (PSOC)

ClinicalTrials.gov ID: NCT07225270

STATUS: Recruiting

SPONSOR: Eli Lilly and Company

LEAD GROUP:  GINECO/NOGGO
ENGOT Model: C
TITLE: A Two-Part Phase 3 Study of Sofetabart Mipitecan (LY4170156) in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Part B) Ovarian Cancer (FRAmework-01)
ClinicalTrials.gov ID:  NCT07213804

MaNGO Sites (will be available soon)

STATUS: Planned

SPONSOR: GSK - GlaxoSmithKline

LEAD GROUP:  AGO
ENGOT Model: C
TITLE: A randomized, multicenter, open-label, Phase 3 study to evaluate GSK5733584 in comparison with chemotherapy in participants with platinum-resistant ovarian cancer
ClinicalTrials.gov ID:  NCT06476184

MaNGO Sites (will be available soon)

STATUS: Planned

SPONSOR: GSK - GlaxoSmithKline

LEAD GROUP:  MaNGO
ENGOT Model: C
TITLE: A Randomized, Multicenter, Open-Label Phase 3 Study to Evaluate the Efficacy of GSK5733584 Combined with Bevacizumab Versus Platinum doublet Combined with Bevacizumab in Patients with Platinum-Sensitive Ovarian Cancer 
ClinicalTrials.gov ID:  NCT07684612

MaNGO Sites (will be available soon)

STATUS: Planned

SPONSOR: MSD - Merck Sharp & Dohme LLC

LEAD GROUP:  MITO
ENGOT Model: C
TITLE: A Phase 3, Randomized, Open-label Study of Raludotatug Deruxtecan (MK-5909, R-DXd) Maintenance Treatment With or Without Bevacizumab Versus Standard of Care in Participants With Newly-Diagnosed Advanced HRD-Negative Ovarian Cancer Following First-line Platinum-based Chemotherapy
ClinicalTrials.gov ID:  NCT07776691

MaNGO Sites (will be available soon)

STATUS: Planned

SPONSOR: Daiichi Sankyo

LEAD GROUP:  GEICO
ENGOT Model: C
TITLE: A randomized, double-blind, multicenter, placebo-controlled, Phase 3 study to evaluate the efficacy and safety of GSK5733584 with or without bevacizumab as maintenance treatment in participants with newly diagnosed FIGO Stage III/IV homologous recombination proficient ovarian, fallopian tube, or primary peritoneal cancer
ClinicalTrials.gov ID:  NCT07791732

MaNGO Sites (will be available soon)

STATUS: Planned

SPONSOR: GSK - GlaxoSmithKline

LEAD GROUP:  MITO
ENGOT Model: C
TITLE: A randomized, double-blind, multicenter, placebo-controlled, Phase 3 study to evaluate the efficacy and safety of GSK5733584 with or without bevacizumab as maintenance treatment in participants with newly diagnosed FIGO Stage III/IV homologous recombination proficient ovarian, fallopian tube, or primary peritoneal cancer
ClinicalTrials.gov ID:  NCT07694427

MaNGO Sites (will be available soon)

STATUS: Planned
SPONSOR: Incyte Corporation

LEAD GROUP: AGO
ENGOT Model: C
TITLE: A Phase 3, Double-Blind, Randomized, Controlled Study of INCB123667 in Combination With Bevacizumab Versus Bevacizumab Alone as First-Line Maintenance Therapy in Participants With Advanced Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Overexpressing Cyclin E1

ClinicalTrials.gov ID: NCT07797283

MaNGO Sites (will be available soon)

STATUS: Planned

SPONSOR: MSD - Merck Sharp & Dohme LLC

LEAD GROUP:  GINECO
ENGOT Model: C
TITLE: A Phase 3, Open-Label, Multicenter, Randomized Study of Raludotatug Deruxtecan (MK-5909, R-DXd) With or Without Bevacizumab Versus Standard-of-Care Platinum-Based Doublet Chemotherapy With or Without Bevacizumab in Participants With Advanced Platinum-Sensitive High-Grade Serous or High-Grade Endometrioid Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Who Have Progressed During First-Line PARPi Maintenance
ClinicalTrials.gov ID:  NCT07743164

MaNGO Sites (will be available soon)

STATUS: Planned

SPONSOR: Zentalis Pharmaceuticals, Inc

LEAD GROUP: GINECO

ENGOT Model: C

TITLE: A Randomized, Open-Label Phase 3 Study of Azenosertib Versus Investigator's Choice of Chemotherapy in Platinum-Resistant High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers Positive for Cyclin E1 Protein Expression

ClinicalTrials.gov ID: NCT07546500

MaNGO Sites (will be available soon)

STATUS: Planned

SPONSOR: Astrazeneca

LEAD GROUP: NOGGO
ENGOT Model: C
TITLE: A Randomised, Open-label, Phase III Study of Torvutatug Samrotecan in Combination With Bevacizumab Versus Bevacizumab Monotherapy as First-line Maintenance Treatment in Participants With Homologous Recombination Deficiency (HRD) Negative Advanced Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (TREVI-OC-02)
ClinicalTrials.gov ID: NCT07851025

MaNGO Sites (will be available soon)

STATUS: Planned
SPONSOR: Genmab

LEAD GROUP: NSGO
ENGOT Model: C
TITLE: Randomized, Open-Label, Phase 3 Study of Rinatabart Sesutecan (Rina-S) Plus Standard of Care Versus Standard of Care as Maintenance Treatment in Participants With Ovarian Cancer Following First-Line (1L) Platinum-Based Chemotherapy

ClinicalTrials.gov ID: NCT07859215

MaNGO Sites (will be available soon)

STATUS: Planned
SPONSOR: AstraZeneca

LEAD GROUP: AGO
ENGOT Model: C
TITLE: A Randomised, Open-label, Phase III Study of Torvutatug Samrotecan With or Without Bevacizumab Versus Standard of Care as Second- or Third-Line Maintenance Treatment in Participants With Platinum-sensitive Relapsed Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (TREVI-OC-03)

ClinicalTrials.gov ID: NCT07816666

MaNGO Sites (will be available soon)